References
- Abraham SN, St John AL. (2010). Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol, 10, 440–52
- Atmar RL, Keitel WA. (2009). Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol, 333, 323–44
- Davies WL, Grunert RR, Haff RF, et al. (1964). Antiviral activity of 1-Adamantanamine (Amantadine). Science, 144, 862–3
- Eisenbarth SC, Colegio OR, O'Connor W, et al. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature, 453, 1122–6
- Friedewald WF. (1944). Adjuvants in immunization with influenza virus vaccines. J Exp Med, 80, 477–91
- Galli SJ, Nakae S, Tsai M. (2005). Mast cells in the development of adaptive immune responses. Nat Immunol, 6, 135–42
- Marshall JS, King CA, McCurdy JD. (2003). Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr Pharm Des, 9, 11–24
- McGowen AL, Hale LP, Shelburne CP, et al. (2009). The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine, 27, 3544–52
- McLachlan JB, Shelburne CP, Hart JP, et al. (2008). Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med, 14, 536–41
- Meng S, Liu Z, Xu L, et al. (2011). Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice. PLoS One, 6, e19863
- Mutsch M, Zhou W, Rhodes P, et al. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med, 350, 896--903
- Nakae S, Suto H, Kakurai M, et al. (2005). Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA, 102, 6467–72
- Nakae S, Suto H, Iikura M, et al. (2006). Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol, 176, 2238--48
- Paton WD. (1951). Compound 48/80: a potent histamine liberator. Br J Pharmacol Chemother, 6, 499–508
- Pizza M, Giuliani MM, Fontana MR, et al. (2001). Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine, 19, 2534–41
- Pulendran B, Ono SJ. (2008). A shot in the arm for mast cells. Nat Med, 14, 489–90
- Rappuoli R, Pizza M, Douce G, Dougan G. (1999). Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today, 20, 493–500
- Reed LJ, Muench H. (1938). A simple method of estimating fifty percent endpoints. Amer J Hyg, 27, 493–7
- Ren SR, Xu LB, Wu ZY, et al. (2010). Exogenous dendritic cell homing to draining lymph nodes can be boosted by mast cell degranulation. Cell Immunol, 263, 204–11
- Rothschild AM. (1970). Mechanisms of histamine release by compound 48-80. Br J Pharmacol, 38, 253–62
- Webby RJ, Webster RG. (2003). Are we ready for pandemic influenza? Science, 302, 1519–22
- Williams NA, Hirst TR, Nashar TO. (1999). Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic. Immunol Today, 20, 95–101
- Xu L, Bao L, Li F, et al. (2011). Adaption of seasonal H1N1 influenza virus in mice. PLoS One, 6, e28901